Aptose Biosciences ROE 2024

Aptose Biosciences Aktienanalyse

What does Aptose Biosciences do?

The company Aptose Biosciences was founded in 1986 and is based in Toronto, Canada. It specializes in the discovery and development of drugs for the treatment of cancer and other serious diseases. History: Aptose Biosciences was originally known as Lorus Therapeutics, specializing in the development of antibodies and peptides. However, in 2007, the company changed its name to Aptose Biosciences and focused on cancer drugs. In 2011, Aptose obtained the license for CG'806, a promising cancer therapy that was later introduced into clinical development in 2017. Business model: Aptose Biosciences' business model is based on the discovery and development of drugs for the treatment of cancer and other serious diseases. The company works closely with leading scientists and researchers to identify and develop new and innovative therapies that have the potential to improve patients' lives. Aptose Biosciences also collaborates with pharmaceutical companies worldwide to advance the development and commercialization of its products. Divisions: Aptose Biosciences focuses on two main areas: the discovery and development of cancer therapies and the discovery of biomarkers that can be used in the diagnosis and treatment of cancer. The cancer therapy division of Aptose focuses on the development of drugs that can target the causes of cancer. The company utilizes innovative technologies to identify and develop new and promising drug candidates that have the potential to improve the lives of patients with various types of cancer. The biomarker division of Aptose focuses on the discovery of biomarkers that can be useful in the diagnosis and treatment of cancer. The company collaborates closely with other companies and research institutions to identify and validate new biomarkers that can contribute to the improvement of cancer diagnosis and treatment. Products: Aptose Biosciences currently offers several cancer drugs that are in different stages of clinical development. The most promising product of Aptose Biosciences is CG'806, which is currently in phase 1 clinical development. CG'806 is a first-in-class cancer drug that has the potential to combat multiple types of cancer. Other products of Aptose Biosciences include APTO-253, which is used for the treatment of AML (acute myeloid leukemia), and APTO-267, which is used for the treatment of CLL (chronic lymphocytic leukemia). Additionally, Aptose Biosciences is working on the development of other cancer therapies that are in various stages of development. Conclusion: Aptose Biosciences is a leading biopharmaceutical company focused on the discovery and development of drugs for the treatment of cancer and other serious diseases. The company has several promising cancer therapies in different stages of clinical development, as well as a promising biomarker division specializing in cancer diagnosis and treatment. With a strong focus on innovation and collaboration, Aptose Biosciences remains an important player in cancer research and therapy. Aptose Biosciences ist eines der beliebtesten Unternehmen auf Eulerpool.com.

ROE Details

Decoding Aptose Biosciences's Return on Equity (ROE)

Aptose Biosciences's Return on Equity (ROE) is a fundamental metric evaluating the company's profitability relative to its equity. Calculated by dividing net income by shareholder's equity, ROE illustrates how effectively the company is generating profits from shareholders’ investments. A higher ROE represents enhanced efficiency and profitability.

Year-to-Year Comparison

Analyzing Aptose Biosciences's ROE on a yearly basis aids in tracking its profitability trends and financial performance. An increasing ROE suggests enhanced profitability and value generation for shareholders, whereas a declining ROE may indicate issues in profit generation or equity management.

Impact on Investments

Aptose Biosciences's ROE is instrumental for investors assessing the company's profitability, efficiency, and investment attractiveness. A robust ROE indicates the firm’s adeptness at converting equity investments into profits, thereby enhancing its appeal to potential and current investors.

Interpreting ROE Fluctuations

Changes in Aptose Biosciences’s ROE can emanate from variations in net income, equity capital, or both. These fluctuations are scrutinized to evaluate management’s effectiveness, financial strategies, and the inherent risks and opportunities, aiding investors in making informed decisions.

Frequently Asked Questions about Aptose Biosciences Stock

What is the ROE (Return on Equity) of Aptose Biosciences this year?

The ROE of Aptose Biosciences this year is 17.65 undefined.

How has the Return on Equity (ROE) of Aptose Biosciences developed compared to the previous year?

The ROE of Aptose Biosciences has increased by -1,691.25% decreased compared to the previous year.

What impact does a high ROE (Return on Equity) have on investors of Aptose Biosciences?

A high ROE indicates that Aptose Biosciences generates good returns on capital and is successful in monetizing its investments. This is a positive indicator for investors.

What impact does a low ROE (Return on Equity) have on investors of Aptose Biosciences?

A low ROE can indicate that Aptose Biosciences is having difficulties monetizing its investments successfully and can be a negative signal for investors.

How does a change in the ROE (Return on Equity) of Aptose Biosciences affect the company?

A change in ROE (Return on Equity) of Aptose Biosciences can be an indicator of the financial performance of the company and demonstrate how successful the company is compared to other companies in the same industry.

How to calculate the ROE (Return on Equity) of Aptose Biosciences?

The ROE (Return on Equity) is calculated by dividing the company's profit by the total equity. The formula is: ROE = Profit / Total equity.

Which factors influence the ROE (Return on Equity) of Aptose Biosciences?

Some factors that can influence Aptose Biosciences's Return on Equity (ROE) include the efficiency in using equity, the profitability of the company, and the financing structure.

What strategic measures can take to improve the ROE (Return on Equity)?

To improve the Return on Equity (ROE), can take measures such as cost savings, increasing revenue, improving efficiency in the use of equity, and making changes in the financing structure. It is important for the company to conduct a thorough review of its financial situation to determine the best strategic actions to improve ROE.

How much dividend does Aptose Biosciences pay?

Over the past 12 months, Aptose Biosciences paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Aptose Biosciences is expected to pay a dividend of 0 USD.

What is the dividend yield of Aptose Biosciences?

The current dividend yield of Aptose Biosciences is .

When does Aptose Biosciences pay dividends?

Aptose Biosciences pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Aptose Biosciences?

Aptose Biosciences paid dividends every year for the past 0 years.

What is the dividend of Aptose Biosciences?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Aptose Biosciences located?

Aptose Biosciences is assigned to the 'Health' sector.

Wann musste ich die Aktien von Aptose Biosciences kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Aptose Biosciences from 6/11/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 6/11/2024.

When did Aptose Biosciences pay the last dividend?

The last dividend was paid out on 6/11/2024.

What was the dividend of Aptose Biosciences in the year 2023?

In the year 2023, Aptose Biosciences distributed 0 USD as dividends.

In which currency does Aptose Biosciences pay out the dividend?

The dividends of Aptose Biosciences are distributed in USD.